title: Genome wide transcriptome analysis of dendritic cells identifies genes with altered expression in psoriasis.
abstract: Activation of dendritic cells by different pathogens induces the secretion of proinflammatory mediators resulting in local inflammation. Importantly, innate immunity must be properly controlled, as its continuous activation leads to the development of chronic inflammatory diseases such as psoriasis. Lipopolysaccharide (LPS) or peptidoglycan (PGN) induced tolerance, a phenomenon of transient unresponsiveness of cells to repeated or prolonged stimulation, proved valuable model for the study of chronic inflammation. Thus, the aim of this study was the identification of the transcriptional diversity of primary human immature dendritic cells (iDCs) upon PGN induced tolerance. Using SAGE-Seq approach, a tag-based transcriptome sequencing method, we investigated gene expression changes of primary human iDCs upon stimulation or restimulation with Staphylococcus aureus derived PGN, a widely used TLR2 ligand. Based on the expression pattern of the altered genes, we identified non-tolerizeable and tolerizeable genes. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (Kegg) analysis showed marked enrichment of immune-, cell cycle- and apoptosis related genes. In parallel to the marked induction of proinflammatory mediators, negative feedback regulators of innate immunity, such as TNFAIP3, TNFAIP8, Tyro3 and Mer are markedly downregulated in tolerant cells. We also demonstrate, that the expression pattern of TNFAIP3 and TNFAIP8 is altered in both lesional, and non-lesional skin of psoriatic patients. Finally, we show that pretreatment of immature dendritic cells with anti-TNF-α inhibits the expression of IL-6 and CCL1 in tolerant iDCs and partially releases the suppression of TNFAIP8. Our findings suggest that after PGN stimulation/restimulation the host cell utilizes different mechanisms in order to maintain critical balance between inflammation and tolerance. Importantly, the transcriptome sequencing of stimulated/restimulated iDCs identified numerous genes with altered expression to date not associated with role in chronic inflammation, underlying the relevance of our in vitro model for further characterization of IFN-primed iDCs.
authors.affiliation: Institute of Biochemistry, Biological Research Centre of the Hungarian Academy of Sciences, Szeged, Hungary.
authors.forename: Kata
authors.initials: K
authors.lastname: Filkor
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Hegedűs
authors.forename: András
authors.initials: A
authors.lastname: Szász
authors.forename: Vilmos
authors.initials: V
authors.lastname: Tubak
authors.forename: Lajos
authors.initials: L
authors.lastname: Kemény
authors.forename: Éva
authors.initials: É
authors.lastname: Kondorosi
authors.forename: István
authors.initials: I
authors.lastname: Nagy
mesh_terms: D017209:Apoptosis; D002453:Cell Cycle; D002478:Cells, Cultured; D016207:Cytokines / Q000235:genetics / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology / Q000378:metabolism* / Q000473:pathology*; D020869:Gene Expression Profiling; D005786:Gene Expression Regulation; D015894:Genome, Human; D006801:Humans; D007113:Immunity, Innate; D010457:Peptidoglycan / Q000276:immunology; D011565:Psoriasis / Q000235:genetics* / Q000276:immunology / Q000473:pathology; D013203:Staphylococcal Infections / Q000276:immunology; D013211:Staphylococcus aureus / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics / Q000276:immunology
chemical_list: D016207:Cytokines; D010457:Peptidoglycan; D014409:Tumor Necrosis Factor-alpha
references.citation: Nat Rev Immunol. 2008 May;8(5):327-36
references.pmid: 18421305
references.citation: Clin Exp Dermatol. 2012 Jul;37(5):521-6
references.pmid: 22680616
references.citation: J Dermatol Sci. 2013 Sep;71(3):215-6
references.pmid: 23684948
references.citation: Mol Immunol. 2010 Sep;47(15):2435-42
references.pmid: 20663561
references.citation: Crit Care. 2006;10(5):233
references.pmid: 17044947
references.citation: Immunity. 2010 Aug 27;33(2):181-91
references.pmid: 20705491
references.citation: Science. 2000 Sep 29;289(5488):2350-4
references.pmid: 11009421
references.citation: J Leukoc Biol. 2006 May;79(5):913-6
references.pmid: 16641136
references.citation: Mol Immunol. 2011 May;48(9-10):1209-15
references.pmid: 21459448
references.citation: Life Sci. 2009 Mar 27;84(13-14):451-7
references.pmid: 19302817
references.citation: Immunol Rev. 2010 Jul;236:11-27
references.pmid: 20636805
references.citation: Pharmacol Ther. 2003 Nov;100(2):171-94
references.pmid: 14609719
references.citation: Nature. 2007 Jun 21;447(7147):972-8
references.pmid: 17538624
references.citation: Nat Genet. 2009 Feb;41(2):199-204
references.pmid: 19169254
references.citation: J Dermatolog Treat. 2009;20(6):319-27
references.pmid: 19954387
references.citation: Cell. 2008 May 2;133(3):415-26
references.pmid: 18455983
references.citation: J Immunol. 1993 Oct 15;151(8):4399-406
references.pmid: 7691948
references.citation: Nat Rev Immunol. 2012 Jul 13;12(8):557-69
references.pmid: 22790179
references.citation: Nat Med. 2012 May 04;18(5):638
references.pmid: 22561807
references.citation: Immunol Lett. 2007 Dec 15;114(2):59-65
references.pmid: 17928070
references.citation: Science. 1998 Apr 10;280(5361):243-8
references.pmid: 9535647
references.citation: Immunity. 2002 Nov;17(5):583-91
references.pmid: 12433365
references.citation: Immunol Rev. 2006 Oct;213:213-27
references.pmid: 16972906
references.citation: Exp Dermatol. 2011 Sep;20(9):725-31
references.pmid: 21672030
references.citation: Clin Vaccine Immunol. 2012 Dec;19(12):1938-42
references.pmid: 23054742
references.citation: Cell. 2006 Feb 24;124(4):823-35
references.pmid: 16497591
references.citation: Genome Res. 2000 Jul;10(7):1051-60
references.pmid: 10899154
references.citation: J Exp Med. 1998 Nov 2;188(9):1657-68
references.pmid: 9802978
references.citation: Nucleic Acids Res. 2012 Jan;40(Database issue):D109-14
references.pmid: 22080510
references.citation: Nat Genet. 2000 May;25(1):25-9
references.pmid: 10802651
references.citation: J Immunol. 2003 Jan 1;170(1):508-19
references.pmid: 12496438
references.citation: J Invest Dermatol. 2008 Mar;128(3):634-42
references.pmid: 17882269
references.citation: Trends Immunol. 2012 Sep;33(9):449-58
references.pmid: 22721918
references.citation: Clin Dermatol. 2007 Nov-Dec;25(6):568-73
references.pmid: 18021894
references.citation: J Exp Med. 2001 Sep 17;194(6):863-9
references.pmid: 11561001
references.citation: J Immunol. 2005 Apr 15;174(8):5082-91
references.pmid: 15814739
references.citation: Cell. 2007 Dec 14;131(6):1124-36
references.pmid: 18083102
references.citation: Immunity. 2011 Oct 28;35(4):572-82
references.pmid: 22000287
references.citation: Nucleic Acids Res. 1999 Jan 1;27(1):29-34
references.pmid: 9847135
references.citation: PLoS One. 2011;6(7):e22953
references.pmid: 21829563
references.citation: Nucleic Acids Res. 2009 Jan;37(1):1-13
references.pmid: 19033363
references.citation: Immunity. 2011 Jul 22;35(1):82-96
references.pmid: 21723156
references.citation: BMC Microbiol. 2011 May 29;11:122
references.pmid: 21619700
references.citation: Nat Immunol. 2011 Oct 23;12(12):1184-93
references.pmid: 22019834
references.citation: Mol Immunol. 2009 Sep;46(15):2918-30
references.pmid: 19631987
references.citation: Crit Care Med. 2002 Jan;30(1 Supp):S64-S73
references.pmid: 11891406
references.citation: J Rheumatol. 2009 Aug;36(8):1575-9
references.pmid: 19567627
references.citation: Bioessays. 1995 Jun;17(6):471-80
references.pmid: 7575488
references.citation: Immunity. 2002 Nov;17(5):677-87
references.pmid: 12433373
references.citation: Cell Death Differ. 2010 Feb;17(2):316-23
references.pmid: 19730441